Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MabSpace Biosciences
Suzhou, Jiangsu, China
- Ownership
- Private
- Employees
- ~60
- Development stage
- Other
01
Overview
MabSpace advanced first-in-class and best-in-class antibody therapeutics for oncology, securing IND approval for MSB2311 (a differentiated anti-PD-L1) and clinical entry of additional molecules, before merging into Transcenta whose programs (e.g., TST001 for CLDN18.2) have reported promising preclinical and early clinical anti-tumor activity.[2][3][6]
- Therapeutic areas
- NephrologyOncologyOphthalmology
- Modalities
- Monoclonal antibodyAntibody-drug conjugateBiologic
- Industry
- Biotech
02
Partnerships
Ambrx (Antibody-drug conjugate development)[4]
Beyond the preview
Go deeper on MabSpace Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MabSpace Biosciences.